Follow Our Live Coverage of COVID-19 Developments

Barrier-Specific Care Significantly Improves Glycemic Control

Implementation of barrier-specific care paths linked to significant reduction in glycated hemoglobin

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Aug. 22, 2016 (HealthDay News) -- For patients with type 2 diabetes, barrier categories to glycemic control include psychological/support, socioeconomic, and accessibility, and addressing these barriers improves glycemic control, according to a study published online Aug. 11 in Diabetes Care.

Ronnie Aronson, M.D., from LMC Diabetes & Endocrinology in Toronto, and colleagues identified participants from a large Canadian registry, assessed barriers to glycemic control, and implemented strategies to improve glycemic control. Of the 1,379 patients who were eligible for inclusion, 155 were enrolled.

The researchers found that the most common barrier categories were psychological/support (93 percent), socioeconomic (87 percent), and accessibility (82 percent); concordance was high (75 to 94 percent) between participants and certified diabetes educators. None of the barriers could predict hyperglycemia. At 12 months, the mean reduction in hemoglobin A1c (HbA1c) was 17 mmol/mol (1.5 percent) after implementation of barrier-specific care paths (P < 0.01 versus baseline), compared with 5 mmol/mol (0.5 percent) in the source cohort that continued with standard care. During the study there was no significant change noted in the incidence of severe hypoglycemia.

"In registry-identified hyperglycemic patients with type 2 diabetes, the use of barrier-specific care paths significantly improved glycemic control in otherwise refractory patients with persistently elevated HbA1c," the authors write.

Two authors disclosed financial ties to pharmaceutical companies, including Sanofi, which provided study funding.

Full Text (subscription or payment may be required)

Last Updated: